"Interferon Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).
| Descriptor ID |
D007370
|
| MeSH Number(s) |
D12.644.276.374.440.890 D12.776.467.374.440.890 D23.529.374.440.890
|
| Concept/Terms |
Interferon Type I- Interferon Type I
- Type I Interferons
- Interferons, Type I
- Interferons Type I
- Type I Interferon
- Interferon, Type I
|
Below are MeSH descriptors whose meaning is more general than "Interferon Type I".
Below are MeSH descriptors whose meaning is more specific than "Interferon Type I".
This graph shows the total number of publications written about "Interferon Type I" by people in this website by year, and whether "Interferon Type I" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 5 | 1 | 6 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 4 | 6 |
| 2016 | 4 | 2 | 6 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 4 | 5 |
| 2022 | 3 | 1 | 4 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon Type I" by people in Profiles.
-
SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck. Cell Rep. 2023 07 25; 42(7):112823.
-
NFKB2 haploinsufficiency identified via screening for IFN-a2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications. J Allergy Clin Immunol. 2023 04; 151(4):926-930.e2.
-
Increased Type I interferon signaling and brain endothelial barrier dysfunction in an experimental model of Alzheimer's disease. Sci Rep. 2022 10 01; 12(1):16488.
-
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor TÂ cell responses. Cancer Cell. 2022 10 10; 40(10):1145-1160.e9.
-
Myeloid cell interferon responses correlate with clearance of SARS-CoV-2. Nat Commun. 2022 02 03; 13(1):679.
-
The US3 Kinase of Herpes Simplex Virus Phosphorylates the RNA Sensor RIG-I To Suppress Innate Immunity. J Virol. 2022 02 23; 96(4):e0151021.
-
Genetic ancestry effects on the response to viral infection are pervasive but cell type specific. Science. 2021 Nov 26; 374(6571):1127-1133.
-
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8.
-
The Type I interferon antiviral gene program is impaired by lockdown and preserved by caregiving. Proc Natl Acad Sci U S A. 2021 07 20; 118(29).
-
Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol. 2021 11; 17(11):751-764.